Pexa-Vec pexastimogene devacirepvec: Phase III started

SillaJen began the open-label, international Phase III PHOCUS trial to evaluate intratumoral Pexa-Vec in combination with Nexavar sorafenib vs. Nexavar alone in 600 patients who have received prior t...